<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2305233692
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LINID 2 MG/ML SOLUTION FOR INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LINEZOLID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        300
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bag
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        144.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PHARMACEUTICAL WORKS POLPHARMA S.A." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PHARMACEUTICAL WORKS POLPHARMA S.A.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1916]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01XX08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">LINID is an antibiotic of the oxazolidinones group that works by stopping the growth of certain bacteria (germs) that cause infections. It is used to treat pneumonia and some infections in the skin or under the skin. Your doctor will have decided if LINID is suitable to treat your infection.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify"><strong>You should not be treated with LINID:</strong></p><ul><li style="text-align:justify">if you are allergic to linezolid or any of the other ingredients of this medicine.</li><li style="text-align:justify">if you are taking or have taken within the last 2 weeks any medicines known as monoamine oxidase inhibitors (MAOIs for example phenelzine, isocarboxazid, selegiline, moclobemide). These medications may be used to treat depression or Parkinson&rsquo;s disease.</li><li style="text-align:justify">if you are breastfeeding. This is because linezolid LINID passes into breast milk and could affect the baby.</li></ul><p style="text-align:justify"><strong>Warnings and precautions</strong><br />LINID may not be suitable for you if you answer yes to any of the following questions. In this case tell your doctor as he/she will need to check your general health and your blood pressure before and during your treatment or may decide that another treatment is better for you.</p><p style="text-align:justify">Ask your doctor if you are not sure whether these categories apply to you.</p><ul><li style="text-align:justify">Do you have high blood pressure, whether or not you are taking medicines for this?</li><li style="text-align:justify">Have you been diagnosed with an overactive thyroid?</li><li style="text-align:justify">Do you have a tumour of the adrenal glands (phaeochromocytoma) or carcinoid syndrome (caused by tumours of the hormone system with symptoms of diarrhoea, flushing of the skin, wheezing)?</li><li style="text-align:justify">Do you suffer from manic depression, schizoaffective disorder, mental confusion or other mental problems?</li><li style="text-align:justify">Are you taking any of the following medicines?<ul><li style="text-align:justify">decongestant, cold or flu remedies containing pseudoephedrine or phenylpropanolamine;</li><li style="text-align:justify">medicines used to treat asthma such as salbutamol, terbutaline, fenoterol;</li><li style="text-align:justify">antidepressants known as tricyclics or SSRIs (selective serotonin reuptake inhibitors) for example amitriptyline, citalopram, clomipramine, dosulepin, doxepin, fluoxetine, fluvoxamine, imipramine, lofepramine, paroxetine; sertraline;</li><li style="text-align:justify">medicines used to treat migraine such as sumatriptan and zolmitriptan;</li><li style="text-align:justify">medicines used to treat sudden, severe allergic reactions such as adrenaline (epinephrine);</li><li style="text-align:justify">medicines which increase your blood pressure, such as noradrenaline (norepinephrine), dopamine and dobutamine;</li><li style="text-align:justify">medicines used to treat moderate to severe pain, such as pethidine;</li><li style="text-align:justify">medicines used to treat anxiety disorders, such as buspirone;</li><li style="text-align:justify">an antibiotic called rifampicin.</li></ul></li></ul><p style="text-align:justify"><strong>Take special care with LINID</strong><br />Tell your doctor before you are treated with this medicine if you:</p><ul><li style="text-align:justify">bruise and bleed easily</li><li style="text-align:justify">are anaemic (have low red blood cells)</li><li style="text-align:justify">are prone to getting infections</li><li style="text-align:justify">have a history of seizures</li><li style="text-align:justify">have liver problems or kidney problems particularly if you have dialysis</li><li style="text-align:justify">have diarrhoea.</li></ul><p style="text-align:justify">Tell your doctor immediately if during treatment you suffer from</p><ul><li style="text-align:justify">problems with your vision such as blurred vision, changes in colour vision, difficulty in seeing detail or if your field of vision becomes restricted.</li><li style="text-align:justify">Loss of sensitivity in your arms or legs or a sensation of tingling or pricking in your arms or legs.</li><li style="text-align:justify">you may develop diarrhoea while taking or after taking antibiotics, including linezolidLINID. If this becomes severe or persistent or you notice that your stool contains blood or mucus, you should stop taking LINID immediately and consult your doctor. In this situation, you should not take medicines that stop or slow bowel movement.</li><li style="text-align:justify">recurrent nausea or vomiting, abdominal pain or over breathing.</li></ul><p style="text-align:justify"><strong>Other medicines and LINID</strong><br />There is a risk that linezolid LINIDmay sometimes interact with certain other medicines to cause side effects such as changes in blood pressure, temperature or heart rate.</p><p style="text-align:justify">Tell your doctor if you are taking or have taken within the last 2 weeks the following medicines as LINID must not be taken if you are already taking these medicines or have taken them recently. (See also Section 2 above &lsquo;You should not be treated with LINID&rsquo;).</p><ul><li style="text-align:justify">monoamine oxidase inhibitors ( MAOIs for example phenelzine, isocarboxazid, selegiline, moclobemide). These may be used to treat depression or Parkinson&rsquo;s disease.</li></ul><p style="text-align:justify">Also tell your doctor if you are taking the following medicines. Your doctor may still decide to give you LINID, but will need to check your general health and your blood pressure before and during your treatment. In other cases, your doctor may decide that another treatment is better for you.</p><ul><li style="text-align:justify">Decongestant cold or flu remedies containing pseudoephedrine or phenylpropanolamine.</li><li style="text-align:justify">Some medicines used to treat asthma such as salbutamol, terbutaline, fenoterol.</li><li style="text-align:justify">Certain antidepressants known as tricyclics or SSRIs (selective serotonin reuptake inhibitors). There are many of these, including amitriptyline, citalopram, clomipramine, dosulepin, doxepin, fluoxetine, fluvoxamine, imipramine, lofepramine, paroxetine, sertraline.</li><li style="text-align:justify">Medicines used to treat migraine such as sumatriptan and zolmitriptan.</li><li style="text-align:justify">Medicines used to treat sudden, severe allergic reactions such as adrenaline (epinephrine).</li><li style="text-align:justify">Medicines which increase your blood pressure, such as noradrenaline (norepinephrine), dopamine</li><li style="text-align:justify">and dobutamine.</li><li style="text-align:justify">Medicines used to treat moderate to severe pain, such as pethidine.</li><li style="text-align:justify">Medicines used to treat anxiety disorders, such as buspirone.</li><li style="text-align:justify">Medicines that stop blood clotting, such as warfarin.</li></ul><p style="text-align:justify">Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p style="text-align:justify"><strong>LINID with food and drink</strong></p><ul><li style="text-align:justify">You can take LINID either before, during or after a meal.</li><li style="text-align:justify">Avoid eating large amounts of mature cheese, yeast extracts, or soya bean extracts e.g. soy sauce and drinking alcohol, especially draught beers and wine. This is because this medicine may react with a substance called tyramine which is naturally present in some foods to cause an increase in your blood pressure.</li><li style="text-align:justify">If you develop a throbbing headache after eating or drinking, tell your doctor or pharmacist immediately.</li></ul><p style="text-align:justify"><strong>Pregnancy, breast-feeding and fertility</strong><br />The effect of linezolid LINIDin pregnant women is not known. Therefore it should not be taken in pregnancy unless advised by your doctor. If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p style="text-align:justify">You should not breastfeed when using LINID because it passes into breast milk and could affect the baby.</p><p style="text-align:justify"><strong>Driving and using machines</strong><br />LINID may make you feel dizzy or may impair your vision. If this happens, do not drive or operate any machinery. Remember that if you are unwell your ability to drive or operate machinery may be affected.</p><p style="text-align:justify"><strong>LINID contains glucose and sodium.</strong><br /><em>Glucose</em><br />Each 1 ml of LINID solution contains 45.7 mg glucose (13.7 g glucose in one bag). Please tell your doctor or nurse if you are diabetic.</p><p style="text-align:justify"><em>Sodium</em><br />Each 1 ml of LINID solution contains 0.38 mg sodium (114 mg sodium in one bag). Please tell your doctor or nurse if you are on a low sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify"><strong>Adults</strong><br />This medicine will be given to you through a drip (by infusion into a vein) by a doctor or healthcare professional. The usual dose for adults (18 years and older) is 300 ml (600 mg linezolid) twice daily which is given directly into the blood stream (intravenously) by a drip over a period of 30 to 120 minutes.</p><p style="text-align:justify">If you are on kidney dialysis, you should be given LINID after dialysis.</p><p style="text-align:justify">A course of treatment usually lasts 10 to 14 days, but can last up to 28 days. The safety and effectiveness of this medicine have not been established for treatment periods longer than 28 days.</p><p style="text-align:justify">Your doctor will decide how long you should be treated.</p><p style="text-align:justify">While you are taking LINID, your doctor should perform regular blood tests to monitor your blood count.</p><p style="text-align:justify">Your doctor should monitor your eyesight if you take LINID for more than 28 days.</p><p style="text-align:justify"><strong>Use in children and adolescents</strong><br />LINID is not normally used to treat children and adolescents (under 18 years old).</p><p style="text-align:justify"><strong>If you receive more LINID than you should</strong><br />If you are concerned that you may have been given too much LINID, tell your doctor or a nurse at once.</p><p style="text-align:justify"><strong>If you miss a dose of LINID</strong><br />As you will be given this medicine under close supervision, it is very unlikely that you will miss a dose. If you think that you have missed a dose of treatment, tell a doctor or nurse at once.</p><p style="text-align:justify">If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Like all medicines, this medicine can cause side-effects although not everybody gets them.</p><p style="text-align:justify"><strong>Tell your doctor, nurse or pharmacist immediately if you notice any of these side effects during your treatment with LINID:</strong></p><ul><li style="text-align:justify">skin reactions such as red sore skin and flaking (dermatitis), rash, itching, or swelling, particularly around the face and neck. This may be the sign of an allergic reaction and it may be necessary for you to stop taking LINID.</li><li style="text-align:justify">problems with your vision such as blurred vision, changes in colour vision, difficulty in seeing detail or if your field of vision becomes restricted.</li><li style="text-align:justify">severe diarrhoea containing blood and/or mucus (antibiotic associated colitis including pseudomembranous colitis), which in very rare circumstances may develop into complications that are life-threatening.</li><li style="text-align:justify">recurrent nausea or vomiting, abdominal pain or over breathing.</li><li style="text-align:justify">fits or seizures have been reported with LINID. You should let your doctor know if you experience agitation, confusion, delirium, rigidity, tremor, incoordination and seizure while also taking antidepressants known as SSRI&rsquo;s (selective serotonin reuptake inhibitors) (see section 2).</li></ul><p style="text-align:justify">Numbness, tingling or blurred vision have been reported by patients who have been given LINID for more than 28 days. If you experience difficulties with your vision you should consult your doctor as soon as possible.</p><p style="text-align:justify"><strong>Other side effects include:<br />Common side-effects (likely to occur in less than 1 in 10 people):</strong></p><ul><li style="text-align:justify">Fungal infections especially vaginal or oral &ldquo;thrush&rdquo;</li><li style="text-align:justify">Headache</li><li style="text-align:justify">Metallic taste in the mouth</li><li style="text-align:justify">Diarrhoea, nausea or vomiting</li><li style="text-align:justify">Changes in some blood test results including those measuring your kidney or liver function or blood sugar levels</li><li style="text-align:justify">Unexplained bleeding or bruising, which may be due to changes in the numbers of certain cells in the blood which may affect blood clotting or lead to anaemia</li><li style="text-align:justify">Difficulty in sleeping</li><li style="text-align:justify">Increased blood pressure</li><li style="text-align:justify">Anaemia (low red blood cell)</li><li style="text-align:justify">Changes in numbers of certain cells in the blood which may affect your ability to fight infection</li><li style="text-align:justify">Skin rash</li><li style="text-align:justify">Itching skin</li><li style="text-align:justify">Dizziness</li><li style="text-align:justify">Localised or general abdominal pain</li><li style="text-align:justify">Constipation</li><li style="text-align:justify">Indigestion</li><li style="text-align:justify">Localised pain</li><li style="text-align:justify">Fever</li></ul><p style="text-align:justify"><strong>Uncommon side-effects (likely to occur in less than 1 in 100 people):</strong></p><ul><li style="text-align:justify">Inflammation of the vagina or genital area in women</li><li style="text-align:justify">Sensations such as tingling or feeling numb</li><li style="text-align:justify">Blurred vision</li><li style="text-align:justify">&ldquo;Ringing&rdquo; in the ears (tinnitus)</li><li style="text-align:justify">Inflammation of the veins</li><li style="text-align:justify">Dry or sore mouth , swollen, sore, or discoloured tongue</li><li style="text-align:justify">Pain at and around the place where the infusion (drip) was given</li><li style="text-align:justify">Inflammation of the veins (including where the infusion (drip) was given)</li><li style="text-align:justify">A need to urinate more often</li><li style="text-align:justify">Chills</li><li style="text-align:justify">Feeling tired or thirsty</li><li style="text-align:justify">Inflammation of the pancreas</li><li style="text-align:justify">Increased sweating</li><li style="text-align:justify">Changes in proteins, salts or enzymes in the blood which measure kidney or liver function</li><li style="text-align:justify">Convulsions</li><li style="text-align:justify">Hyponatraemia (low blood sodium levels)</li><li style="text-align:justify">Kidney failure</li><li style="text-align:justify">Reduction in platelets</li><li style="text-align:justify">Abdominal bloating</li><li style="text-align:justify">Transient ischaemic attacks (temporary disturbance of blood flow to the brain causing short term symptoms such as loss of vision, leg and arm weakness, slurring of speech and loss of consciousness)</li><li style="text-align:justify">Injection site pain</li><li style="text-align:justify">Inflammation of the skin</li><li style="text-align:justify">Increase in creatinine</li><li style="text-align:justify">Stomach pain</li><li style="text-align:justify">Changes in heart rate (eg, increase rate)</li></ul><p style="text-align:justify"><strong>Rare side-effects (likely to occur in less than 1 in 1000 people):</strong></p><ul><li style="text-align:justify">Restricted field of vision</li><li style="text-align:justify">Superficial tooth discolouration, removable with professional dental cleaning (manual descaling)</li></ul><p style="text-align:justify"><strong>The following side effects have also been reported (frequency not known):</strong></p><ul><li style="text-align:justify">Serotonin syndrome (symptoms include fast heart rate, confusion, abnormal sweating, hallucinations, involuntary movements chills and shivering),</li><li style="text-align:justify">Lactic acidosis (symptoms include recurrent nausea and vomiting, abdominal pain, overbreathing)</li><li style="text-align:justify">Severe skin disorders</li><li style="text-align:justify">Sideroblastic anaemia (a type of anaemia (low red blood cells))</li><li style="text-align:justify">Alopecia (hair loss)</li><li style="text-align:justify">Changes in colour vision or difficulty in seeing detail</li><li style="text-align:justify">Decrease of the blood cell count</li><li style="text-align:justify">Weakness and/or sensory changes</li></ul><p style="text-align:justify">If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Hospital Staff will make sure that LINID solution is not used after the expiry date printed on the bag and that it is given to you as soon as the seal is broken. A month and year are stated on the bag. The expiry date refers to the last day of that month. Hospital Staff will also visually inspect the solution prior to use and only clear solution, without particles will be used. They will also make sure that the solution is kept correctly in its box in order to protect from light and out of the sight and reach of children until it is needed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">- The active substance is linezolid. 1 ml of solution contains 2 mg linezolid.<br />- The other ingredients are glucose monohydrate (a type of sugar), sodium citrate (E331), citric acid anhydrous (E330), hydrochloric acid (E507) or sodium hydroxide (E524) and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                LINID is presented as a clear solution in single polyethylene infusion bags containing 300 ml(600mg linezolid) of solution.
The bags are supplied in boxes of 1 bags.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong><br />AJA Pharmaceutical Industries Company, Ltd.<br />G FLOOR, ZONE C2, THE BUSINESS GATE, CORDOBA<br />Riyadh Saudi Arabia<br />Tel: +966 11 268 7900</p><p><strong>Manufacturer</strong><br />Pharmaceutical Works Polpharma S.A.<br />19, Pelplinska Str.<br />83-200 Starogard Gdanski<br />Poland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 01/2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p style="text-align:justify">لينيد هو مضاد حيوي من مجموعة الأوكزاليدينون والذي يعطي مفعوله من&nbsp;خلال وقف نمو&nbsp;أنواع&nbsp;معينة من&nbsp;البكتيريا (الجراثيم)&nbsp;التي&nbsp;تسبب&nbsp;العدوى. ويستعمل لعلاج الالتهاب الرئوي وبعض أمواع الإصابات بالجلد او تحت الجلد. والطبيب هو الذي يقرر ما إذا كان لينيد هو العلاج المناسب لإصابتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify">يجب أن لاتعالج بـ&quot;لينيد&quot; في الحالات التالية:</p><ul><li style="text-align:justify">إذا كانت لديك حساسية للينيزوليد أو أي من المكونات الأخرى لهذا الدواء.</li><li style="text-align:justify">إذا كنت تستعمل حاليا أو استعملت خلال الأسبوعين الماضيين أي دواء من المجموعة التي تسمى مثبطات احادي امين اوكسيديز (MAOIs) مثل فينيلزين، ايزوكاربوكسازيد، سيليجيلين، موكلوبيميد. وهي أدوية تستعمل لعلاج الاكتئاب أو مرض باركنسون</li><li style="text-align:justify">المرأه المرضع يجب أن لاتستعمل لينيزوليد لأنه يفرز في حليب الأم ويمكن أن يؤثر علآ الرضيع</li></ul><p style="text-align:justify"><strong>تحذيرات واحتياطات</strong></p><p style="text-align:justify">قد لايكون لينيد مناسبا لك إذا كانت إجابتك بنعم على أي من الأسئلة التالية. وفي مثل تلك الحالة يجب أن تبلغ طبيبك الذي سيقوم بفحصك وتقييم حالتك الصحية العامة وضغط الدم قبل وأثناء استعمالك العلاج وقد يقرر أن من الأفضل لك استعمال نوع آخر من الأدوية.</p><p style="text-align:justify">اسأل طبيبك إذا كنت غير متأكد ما أن كانت أي من النقاط التالية تنطبق عليك:</p><ul><li dir="rtl" style="text-align:justify">هل تعاني من ارتفاع ضغط الدم، وهل تستعمل أي دواء لهذه المشكلة؟</li><li dir="rtl" style="text-align:justify">هل تم تشخيص إصابتك بفرط نشاط الغدة الدرقية؟</li><li dir="rtl" style="text-align:justify">هل أنت مصاب بورم في الغدة الكظرية (ورم الخلايا الكروماتية القاتمة)، أو متلازمة تسرطن (ناتجة عن أورام بالجهاز الهرموني مع أعراض الإسهال وحماوية احمرار الجلد، أزيز تنفسي)؟</li><li dir="rtl" style="text-align:justify">هل تستعمل أي من الأدوية التالية:<ul><li style="text-align:justify">مزيلات&nbsp;الاحتقان، أو أدوية الزكام والإنفلونزا المحتوية على بسودو ايفيدرين أو فينيل بروبانول امين</li><li style="text-align:justify">أدوية تستعمل لعلاج الربو مثل سالبيوتامول، أو تيربيوتاميل، أو فينوتيرول.</li><li style="text-align:justify">مضادات الاكتئاب التي تعرف بالمركبات الحلقية الثلاثية أو مثبطات اعادة امتصاص السيروتونين الإنتقائية (SSRIs) على سبيل المثال: اميتربتولين، سيتالوبرام، كلوميبرامين، دوسوليبين، دوكسيبين، فلوكسيتين، فلوفوكسامين، اميبرامين، لوفيبرامين، باروكسيتين، سيرترالبن.</li><li style="text-align:justify">أدوية تستعمل لعلاج الصداع النصفي (الشقيقة) مثل سوماتربتان، وزولميتربتان.</li><li style="text-align:justify">أدوية تستعمل لعلاج ردات الفعل التحسسية الشديدة المفاجئة: ادرينالين (ابينفرين)</li><li style="text-align:justify">الأدوية التي ترفع من ضغط الدم مثل نور ادرينالين (نور ابينفرين)، ودوبامين، ودبيوتامين.</li><li style="text-align:justify">أدوية تستعمل لعلاج الآلام المتوسطة والشديدة مثل: بيثيدين</li><li style="text-align:justify">أدوية تستعمل لعلاج القلق مثل: بسبيرون</li><li style="text-align:justify">المضاد الحيوي ريفامبيسين</li></ul></li></ul><p style="text-align:justify">يجب توخي الحذ بخصوص استعمال لينيد، وعليك تبليغ طبيبك إذا كانت لديك الحالات التالية:</p><ul><li style="text-align:justify">سهولة النزيف والإصابة بالكدمات.</li><li style="text-align:justify">الأنيميا أو فقر الدم (نقص عدد كريات الدم الحمراء).</li><li style="text-align:justify">إذا كنت عرضة للعدوى أو الالتهابات المتكررة.</li><li style="text-align:justify">لديك تاريخ للإصابة بتشنجات الصرع.</li><li style="text-align:justify">لديك مشاكل في الكبد أو الكلى وخاصة إذا كنت تعالج بغسيل الدم.</li><li style="text-align:justify">تعاني من الإسهال.</li></ul><p style="text-align:justify">يجب إبلاغ طبيبك فورا إذا لاحظت أيا مما يلي أثناء استعمال هذا الدواء:</p><ul><li style="text-align:justify">مشاكل في النظر مثل ضبابية الرؤية أو تغيرات في الألوان أو صعوبة في تحديد التفاصيل أو نقص في حقول الإبصار.</li><li style="text-align:justify">فقد الإحساس أو شعور بالتنميل أو الوخز في الذراعين أو الرجلين.</li><li style="text-align:justify">يمكن أن تصاب الإسهال أثناء أو بعد استعمال المضادات الحيوية بما فيها لينيزوليد، فأذا اشتد الإسهال او استمر أو لاحظت ان البراز يحتوي على الدم أو المخاط فيجب وقف لينيد فوراً واستشارة الطبيب. وفي هذه الحالة يجب أن لا تتناول أدوية تؤدي إلى وقف أو إبطاء حركة الأمعاء (حدوث إمساك)</li><li style="text-align:justify">غثيان أو قيء متكرر أو ألم في البطن أو تسارع التنفس.</li></ul><p style="text-align:justify"><strong>الأدوية الأخرى ولينيد</strong></p><p style="text-align:justify">هناك مخاطر ان يتفاعل لينيزوليد احيانا مع انواع معينة من الأدوية مما يتسبب في تأثيرات جانبية مثل التغيرات في ضغط الدم أو حرارة الجسم أو النبض.</p><p style="text-align:justify">اخبر طبيبك إذا كنت تتناول أيا من الأدوية التالية أو تناولتها خلال الأسبوعين الماضيين حيث انه يجب&nbsp;<strong>عدم استعمال لينيد</strong>&nbsp;إذا كنت تستعمل تلك الأدوية او استعملتها حديثاً. (انظر للفقرة رقم-2 أعلاه <strong>يجب أن لا تُعالج بـ&quot;لينيد&quot;</strong>)</p><ul><li style="text-align:justify">مثبطات احادي امين اوكسيديز (MAOIs) مثل فينيلزين، ايزوكاربوكسازيد، سيليجيلين، موكلوبيميد.&nbsp;وهي أدوية تستعمل لعلاج الاكتئاب أو مرض باركنسون.</li></ul><p style="text-align:justify">كما يجب أن تخبر طبيبك إذا كنت تتناول أيا من الأدوية المذكورة أدناه وقد يقرر الطبيب أن يعطيك لينيد ولكنه قبل ذلك سيجري لك بعض الفحوصات للتأكد من حالتك الصحية العامة وضغط الدم قبل وأثناء استعمالك العلاج وقد يقرر أن من الأفضل لك استعمال نوع آخر من الأدوية:</p><ul><li dir="rtl" style="text-align:justify">مزيلات&nbsp;الاحتقان، أو أدوية الزكام والإنفلونزا المحتوية على بسودو ايفيدرين أو فينيل بروبانول امين</li><li dir="rtl" style="text-align:justify">أدوية تستعمل لعلاج الربو مثل سالبيوتامول، أو تيربيوتاميل، أو فينوتيرول.</li><li dir="rtl" style="text-align:justify">مضادات الاكتئاب التي تعرف بالمركبات الحلقية الثلاثية أو مثبطات اعادة امتصاص السيروتونين الإنتقائية (SSRIs) على سبيل المثال: اميتربتولين، سيتالوبرام، كلوميبرامين، دوسوليبين، دوكسيبين، فلوكسيتين، فلوفوكسامين، اميبرامين، لوفيبرامين، باروكسيتين، سيرترالين.</li><li dir="rtl" style="text-align:justify">أدوية تستعمل لعلاج الصداع النصفي (الشقيقة) مثل سوماتربتان، وزولميتربتان.</li><li dir="rtl" style="text-align:justify">أدوية تستعمل لعلاج ردات الفعل التحسسية الشديدة المفاجئة: ادرينالين (ابينفرين)</li><li dir="rtl" style="text-align:justify">الأدوية التي ترفع من ضغط الدم مثل نور ادرينالين (نور ابينفرين)، ودوبامين، ودبيوتامين.</li><li dir="rtl" style="text-align:justify">أدوية تستعمل لعلاج الآلام المتوسطة والشديدة مثل: بيثيدين</li><li dir="rtl" style="text-align:justify">أدوية تستعمل لعلاج القلق مثل: بسبيرون</li><li dir="rtl" style="text-align:justify">الأدوية التي تمنع تجلط الدم مثل وارفرين</li></ul><p style="text-align:justify">يرجى ابلاغ الطبيب أو الصيدلي إذا كنت تستعمل أو استعملت حديثا أي أدوية أخرى بما فيها تلك الأدوية التي يمكن الحصول عليها بدون وصفة طبية.</p><p style="text-align:justify"><strong>لينيد مع الطعام والشراب</strong></p><p style="text-align:justify">يمكنك استعمال لينيد قبل أو أثناء أو بعد تناول وجبة غذائية.</p><p style="text-align:justify">تجنب تناول كميات كبيرة من الجبنة الناضجة وخلاصة الخميرة أو خلاصات فول الصويا مثل صلصة الصويا أو تناول المشروبات الكحولية خاصة البيرة والنبيذ. وذلك لأن هذا الدواء يتفاعل مع مادة تسمى تيرامين الموجودة بصورة طبيبعة في بعض أنواع الأطعمة ويؤدي ذلك التفاعل إلى ارتفاع ضغط&nbsp; الدم.</p><p style="text-align:justify">إذا اصبت بصداع من النوع النابض بعد تناول الطعام او الشراب فيجب ابلاغ الطبيب أو الصدلي فورا.</p><p style="text-align:justify">الحمل والرضاعة والخصوبة</p><p style="text-align:justify">لا يعرف تأثير لينيزوليد على المرأه الحامل، يجب عدم استعماله أثناء الحمل ما لم ينصح بذلك الطبيب. وبالنسبة للمرأه الحامل أو التي تظن أنها حامل أو تنوي الحمل يجب عليها استشارة الطبيب أو الصيدلي قبل استعمال هذا الدواء.</p><p style="text-align:justify">كما يجب عدم ارضاع الطفل أثناء استعمال لينيد حيث أنه يفرز في حليب الثدي ويمكن أن يؤثر على الطفل الرضيع.</p><p style="text-align:justify"><strong>قيادة المركبات وتشغيل الآلات</strong></p><p style="text-align:justify">قد يسبب لينيد الشعور بالدوار أو القصور في الإبصار، فإذا حدث ذلك يجب عدم قيادة المركبات أو تشغيل الآلات. ويجب أن تتذكر أنك إذا كنت تشعر بالتوعك أو اعتلال الصحة فإن قدرتك على فيادة المركبات أو تشغيل الآلات سوف تتأثر سلباً.</p><p style="text-align:justify"><strong>لينيد يحتوي على الجلوكوز و الصوديوم</strong></p><p style="text-align:justify"><em>الجلوكوز</em></p><p style="text-align:justify">كل 1 مل من محلول لينزوليد يحتوي على 45.7 ملغم جلوكلوز (13.7 عرام جلوكوز في الكيس الواحد) يرجى إبلاغ طبيبك أو الممرضة إذا كنت مصابا بمرض السكري.</p><p style="text-align:justify"><em>الصوديوم</em></p><p style="text-align:justify">كل 1 مل من محلول لينيزوليد يحتوي على 0.38 مغلم من الصوديوم ( 114غرام ملغم صوديوم في الكيس الواحد). يرجى إيلاغ طبيبك أو الممرضة إذا كنت تتبع حمية غذائية قليلة الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify">يعطى هذا الدواء بطريقة التنقيط الوريدي تحت إشراف طبيب أو مهني مختص في الرعاية الصحية. الجرعة المعتادة للبالغين (في عمر 18 عاما فما فوق) هي 300 مل (600 ملغم لينيزوليد) مرتين يوميا وتعطى هذه الجرعة في الدورة الدموية مباشرة (بالوريد) بطريقة التنقيط الوريدي على مدى فترة 30 إلى 120 دقيقة.</p><p style="text-align:justify">إذا كنت تعالج بجلسات غسيل الدم فيجب أن تعطى لينيد بعد الجلسة.</p><p style="text-align:justify">مدة العلاج تستمر عادة من 10 إلى 14 يوماً ويمكن أن تمتد لغاية 28 يوماً. ولم تتأكد سلامة وفعالية استمرار العلاج لفترات تزيد عن 28 يوما.</p><p style="text-align:justify">سوف يقرر الطبيب مدة العلاج المناسبة لحالتك.</p><p style="text-align:justify">خلال فترة استعمال لينيد سوف يجري الطبيب لك بعض الفحوصات وتحاليل الدم لمراقبة عدد مكونات الدم. كما سيقوم بمراقبة الإبصار لديك إذا زادت فترة استعمال لينيد عن 28 يوماً.</p><p style="text-align:justify"><strong>الاستعمال لدى الأطفال والمراهقين</strong></p><p style="text-align:justify">لايعطى لينيد عادة للأطفال والمراهقين (الذين تقل أعمارهم عن 18 عاما)</p><p style="text-align:justify"><strong>إذا تناولت جرعة زائدة من لينيد</strong></p><p style="text-align:justify">إذا ساورك الشك بأنه قد اعطيت لك جرعة زائدة يجب ان تبلغ الطبيب أو الممرضة بذلك فورا.</p><p style="text-align:justify"><strong>إذا نسيت أن تتناول لينيد</strong></p><p style="text-align:justify">حيث ان إعطاء هذا الدواء يكون تحت مراقبة وثيقة فمن المستبعد ان تغفل&nbsp;او تفوتك&nbsp;جرعة. ولكن إذا ساورك الشك أنه قد تم إغفال او نسيان جرعة فيجب ان تبلغ الطبيب أو الممرضة بذلك.</p><p style="text-align:justify">إذا كان لديك أي اسئلة حول استعمال هذا الدواء فيجب ان تسأل الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify">هذا الدواء كغيره من الأدوية يمكن أن يسبب بعض الآثار الجانبية ولكنها ليس بالضرورة تحدث لدى جميع الأشخاص.</p><p style="text-align:justify"><strong>يجب عليك إبلاغ الطبيب أو الصيدلي فوراً&nbsp;</strong>إذا حدث لديك أي من الأعراض التالية أدناه من جراء تناول لينيد:</p><ul><li style="text-align:justify">ردود فعل بالجلد مثل احمرار مصحوب بألم وتقشر في الجلد (التهاب الجلد)، طفح جلدي، حكه، تورم، خاصة بالوجه والعنق. فقد يكون ذلك من علامات ردة فعل الحساسية وقد يتوجب وقف استعمال لينيد.</li><li style="text-align:justify">مشاكل في النظر مثل الضبابية والزغللة وتغير الألوان وصعوبة تمييز التفاصيل أو نقص حقول الإبصار.</li><li style="text-align:justify">إسهال شديد يحتوي على دم أو مخاط (التهاب القولون المرتبط باستعمال المضادات الحيوية بما في ذلك التهاب القولون الناتج عن الإصابة ببكتيريا من نوع &quot;سودومونس&quot;) الذي يمكن في حالات نادرة جدا أن يتطور إلى مضاعفات تهدد حياة المصاب.</li><li style="text-align:justify">نوبات غثيان أو تقيؤ متكررة أو تسارع التنفس.</li><li style="text-align:justify">تم الإبلاغ عن نوبات تشنج أو صرع عند استعمال لينيد. يجب إبلاغ الطبيب إذا لاحظت ايا من اعراض التكدر أو الهذيان أو التصلب أو الإرتباك أو الارتعاشات، أو عدم التناسق الحركي أو التشنجات أثناء استعمال مضادات الاكتئاب بمثبطات اعادة امتصاص السيروتونين الانتقائية (SSRIs).</li></ul><p style="text-align:justify">وقد تم الإبلاغ عن أعراض ضبابية الرؤيا لدى مرضى تم إعطائهم لينيد لمدة تزيد عن 28 يوما. فإذا لاحظت أي مصاعب أو مشاكل في النظر يجب عليك استشارة الطبيب في أسرع وقت ممكن.</p><p style="text-align:justify">تأثيرات جانبية أخرى:</p><p style="text-align:justify"><strong>تأثيرات شائعة (يمكن أن تحدث لدى أقل من 1 من بين كل 10 أشخاص)</strong></p><ul><li style="text-align:justify">اصابات فطرية خاصة في المهبل أو الفم &quot;القلاع&quot;.</li><li style="text-align:justify">صداع.</li><li style="text-align:justify">طعم معدني في الفم.</li><li style="text-align:justify">إسهال، أو غثيان أو قيء.</li><li style="text-align:justify">تغيرات في نتائج بعض تحاليل الدم بما في ذلك تلك التي تقيس وظائف الكلى أو الكبد أو مستويات الجلوكوز في الدم.</li><li style="text-align:justify">نزيف أو كدم غير معروف السبب الذي قد يكون ناتجا عن تغيرات في عدد بعض أنواع الخلايا الدموية والتي قد تؤثر على تخثر الدم أو تؤدي إلى الأنيميا.</li><li style="text-align:justify">صعوبة في النوم.</li><li style="text-align:justify">ارتفاع ضغط الدم.</li><li style="text-align:justify">أنيميا أو فقر الدم (انخفاض عدد خلايا الدم الحمراء)</li><li style="text-align:justify">تغيرات في اعداد بعض الخلايا الدموية والتي قد تؤثر على قدرة الشخص في مقاومة العدوى.</li><li style="text-align:justify">طفح جلدي.</li><li style="text-align:justify">حكة بالجلد.</li><li style="text-align:justify">دوار.</li><li style="text-align:justify">ألم موضعي أو عام في البطن.</li><li style="text-align:justify">إمساك.</li><li style="text-align:justify">عسر هضم.</li><li style="text-align:justify">آلام موضعية.</li><li style="text-align:justify">حمى (ارتفاع درجة الحرارة)</li></ul><p style="text-align:justify"><strong>تأثيرات غير&nbsp;شائعة (يمكن أن تحدث لدى أقل من 1 من بين كل 100 أشخاص)</strong></p><ul><li style="text-align:justify">التهاب المهبل أو منطقة الأعضاء التناسيلة لدى النساء</li><li style="text-align:justify">إحساس بالخدر أو التنميل</li><li style="text-align:justify">ضبابية في النظر</li><li style="text-align:justify">طنين في الإذن</li><li style="text-align:justify">التهاب الأوردة</li><li style="text-align:justify">جفاف أو تورم الفم أو اللسان وتغير لونه</li><li style="text-align:justify">ألم بمنطقة إدخال الحقنة الوريدية أو حولها</li><li style="text-align:justify">التهاب الأوردة (بما فيها موضع ادخال الحقنة الوريدية وحولها)</li><li style="text-align:justify">زيادة وتكرار الرغبة في التبول</li><li style="text-align:justify">قشعريرة</li><li style="text-align:justify">شعور بالتعب والنعاس</li><li style="text-align:justify">التهاب البنكرياس</li><li style="text-align:justify">زيادة التعرق</li><li style="text-align:justify">تغيرات في البروتينات والأملاح والأنزيمات في الدم والتي تقيس وظائف الكلى أو الكبد</li><li style="text-align:justify">تشنجات عضلية</li><li style="text-align:justify">انخفاض مستوى الصوديوم في الدم</li><li style="text-align:justify">&nbsp;فشل كلوي</li><li style="text-align:justify">نقص الصفائح الدموية</li><li style="text-align:justify">انتفاخ بالبطن</li><li style="text-align:justify">نوبات فقر دم موضعي مؤقتة (خلل مؤقت في تدفق الدم للدماغ مسبباً بعض الأعراض المؤقتة لفترات قصيرة مثل فقد البصر، ضعف الذراعين والرجلين تلعثم وخلل في النطق وفقدان للوعي)</li><li style="text-align:justify">ألم في موضع الحقن</li><li style="text-align:justify">التهاب الجلد</li><li style="text-align:justify">ارتفاع مستوى الكرياتنين</li><li style="text-align:justify">ألم بالمعدة</li><li style="text-align:justify">تغيرات في سرعة النبض (زيادة سرعة النبض)</li></ul><p style="text-align:justify"><strong>تأثيرات نادرة (معدل الحدوث غير معروف)</strong></p><ul><li style="text-align:justify">محدودية حقول الإبصار</li><li style="text-align:justify">تغير سطحي في لون الأسنان يمكن إزالته بواسطة اخصائيين محترفين في تنظيف الأسنان</li></ul><p style="text-align:justify"><strong>التأثيرات الجانبية التالية ادناه تم الإبلاغ عن حدوثها (معدل الحدوث غير معروف)</strong></p><ul><li style="text-align:justify">متلازمة سيروتونين (تشمل الأعراض تسارع النبض، والإرتباك، والتعرق غير الطبيعي، والهلوسة، وحركات لا إرادية، وقشعريرة وارتجاف)</li><li style="text-align:justify">خلل شديد بالجلد</li><li style="text-align:justify">انيميا نقص الحديد (نوع من الأنيميا يتميز بانخفاض كريات الدم الحمراء)</li><li style="text-align:justify">الثعلبة (فقدان الشعر في مناطق معينة)</li><li style="text-align:justify">تغيرات في رؤيا الألوان أو صعوبة في رؤية التفاصيل</li><li style="text-align:justify">نقص في عدد كريات الدم</li><li style="text-align:justify">ضعف و/أو تغيرات في الإحساس</li></ul><p style="text-align:justify">إذا ظهرت لديك أي من التأثيرات الجانبية فيجب التحدث إلى الطبيب أو الصيدلي. وتشمل تلك الأعراض اي تأثيرات محتمله اخرى لم يرد ذكرها في هذه النشرة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify">سيقوا العاملون في المستشفى أو المركز الصحي&nbsp;على الدوام بالتأكد من&nbsp;عدم استعمال لينيد&nbsp;بعد تاريخ&nbsp;انتهاء صلاحيته المطبوع على العبوة (الكيس)، وأنه سيعطى لك بعد فتح العبوة مباشرة.</p><p style="text-align:justify">تاريخ انتهاء الصلاحية مكتوب بالشهر والسنة ويشير إلى آخر يوم من ذلك الشهر. ويقوم العاملون في المستشفى بفحص المحلول بالنظر قبل استعماله ولايعطى لك الا المحلول الصافي بدون أي شوائب أو ذرات. كما يتم التأكد من أن المحلول موجود في العلبة الأصلية ومحمي من الضوء وبعيدا عن متناول الأطفال لحين الحاجة إليه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify">المادة الفعالة هي &quot;لينيزوليد&quot; . وكل 1 مل من المحلول يحتوي على 2 مل من&nbsp;لينيزوليد</p><p style="text-align:justify">المكونات الأخرى هي: جلوكنوز احادي مائي (أحد أنواع السكر)، سترات الصوديوم (إي 331) ، حامض الستريك اللامائي (إي 330)، حامض هيدروكلوريك (إي 507) أو هيدروكسيد الصوديوم (إي 524)، ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>لينيند محلول للحقن&nbsp;متوفر في اكياس بولي إيثيلين&nbsp;خاصة لتنقيط الوريدي&nbsp;تحتوي كل منها على&nbsp;300 مل من المحلول (600 ملغم لينيزوليد)</p><p>الأكياس تورد في علب كل منها يحتوي على كيس واحد</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>حامل حق التسويق</strong><br />شركة آجا للصناعات الدوائية المحدودة<br />الدور الأرضي, المنطقة 2 ج, البوابة الاقتصادية, حي قرطبة, الرياض, المملكة العربية السعودية.<br />هاتف 7900 268 11 966+</p><p><strong>الشركة المصنعة</strong><br />فارماسوتيكال ووركس بولفارما اس. أي<br />19 شارع بيلبليسكا<br />200 - 80 ستاروجارد جدانسكي<br />بولندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 01/2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LINID 2 mg/ml, solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml contains 2 mg linezolid. Infusion bags filled with 300 ml contain 600 mg linezolid. This medicinal product contains 1,67 mmol (or 114 mg) sodium per dose.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for infusion.
Isotonic, clear colourless solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li style="text-align: justify;">Nosocomial pneumonia</li><li style="text-align: justify;">Community acquired pneumonia</li></ul><p style="text-align:justify">LINID is indicated in adults for&nbsp; the&nbsp; treatment&nbsp; of&nbsp; community&nbsp; acquired&nbsp; pneumonia&nbsp; and&nbsp; nosocomial&nbsp; pneumonia&nbsp; when&nbsp; known&nbsp; or&nbsp; suspected&nbsp; to&nbsp; be&nbsp; caused&nbsp;&nbsp; by&nbsp;&nbsp; susceptible&nbsp;&nbsp; Gram&nbsp;&nbsp; positive bacteria. In determining whether LINID is an appropriate treatment, the results of microbiological tests or information on the&nbsp; prevalence&nbsp; of&nbsp; resistance&nbsp; to&nbsp; antibacterial&nbsp; agents&nbsp; among Gram positive bacteria should be taken into consideration (see section 5.1 for&nbsp; the&nbsp; appropriate organisms).</p><p style="text-align:justify">Linezolid is&nbsp; not&nbsp; active&nbsp; against&nbsp; infections&nbsp; caused&nbsp; by&nbsp; Gram&nbsp; negative&nbsp; pathogens.&nbsp; Specific&nbsp; therapy against Gram negative organisms must be initiated concomitantly if a Gram negative pathogen is documented or suspected.</p><p style="text-align:justify">Complicated skin and soft tissue infections (see section 4.4)</p><p style="text-align:justify">LINID is indicated in adults for the&nbsp; treatment&nbsp; of&nbsp; complicated&nbsp; skin&nbsp; and&nbsp; soft&nbsp; tissue&nbsp; infections&nbsp; <strong>only&nbsp; </strong>when&nbsp; microbiological&nbsp; testing&nbsp; has&nbsp; established&nbsp; that&nbsp; the&nbsp;&nbsp; infection&nbsp;&nbsp; is&nbsp;&nbsp; known&nbsp;&nbsp; to&nbsp;&nbsp; be&nbsp;&nbsp; caused by susceptible Gram positive bacteria.</p><p style="text-align:justify">Linezolid is not active against infections caused by Gram negative pathogens. Linezolid should&nbsp; &nbsp;only be used in patients with&nbsp; complicated&nbsp; skin&nbsp; and&nbsp; soft&nbsp; tissue&nbsp; infections&nbsp; with&nbsp; known&nbsp; or&nbsp; possible co-infection with Gram negative organisms if there are no alternative treatment options available (see section 4.4). In these circumstances treatment&nbsp; against&nbsp; Gram&nbsp; negative&nbsp; organisms <u>must</u> be initiated concomitantly.</p><p style="text-align:justify">Linezolid should only be initiated in a hospital environment and after consultation with a relevant specialist such as a microbiologist or infectious diseases specialist.</p><p style="text-align:justify">Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Posology</u></p><p style="text-align:justify">LINID solution for infusion may be used as initial therapy.</p><p style="text-align:justify">Patients who commence treatment on the parenteral formulation may be switched to either oral presentation when clinically indicated.</p><p style="text-align:justify">In such circumstances, no dose adjustment is required as linezolid has an oral bioavailability of approximately 100%.</p><p style="text-align:justify"><em><u>Recommended dosage and duration of treatment for adults:</u></em></p><p style="text-align:justify">The duration of treatment is dependent on the pathogen, the site of infection and its severity, and on the patient&#39;s clinical response.</p><p style="text-align:justify">The following recommendations for duration of therapy reflect those used in the clinical trials. Shorter treatment regimens may be suitable for some types of infection but have not been evaluated in clinical trials.</p><p style="text-align:justify">The maximum treatment duration is 28 days. The safety and effectiveness of linezolid when administered for periods longer than 28 days have not been established (see section 4.4).</p><p style="text-align:justify">No increase in the recommended dosage or duration of treatment is required for infections associated with concurrent bacteraemia.</p><p style="text-align:justify">The dose recommendation is as follows:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>Infections</strong></p></td><td style="vertical-align:top"><p style="text-align:justify"><strong>Dosage</strong></p></td><td style="vertical-align:top"><p style="text-align:justify"><strong>Duration of treatment</strong></p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Nosocomial pneumonia</p></td><td style="vertical-align:top"><p style="text-align:justify">600 mg intravenously twice daily</p></td><td style="vertical-align:top"><p style="text-align:justify">10-14 Consecutive days</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Community acquired pneumonia</p></td><td style="vertical-align:top"><p style="text-align:justify">600 mg intravenously twice daily</p></td><td style="vertical-align:top"><p style="text-align:justify">10-14 Consecutive days</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Complicated skin and soft tissue infections</p></td><td style="vertical-align:top"><p style="text-align:justify">600 mg intravenously twice daily</p></td><td style="vertical-align:top"><p style="text-align:justify">10-14 Consecutive days</p></td></tr></tbody></table><p style="text-align:justify"><em>Paediatric population:</em></p><p style="text-align:justify">There are insufficient data on&nbsp; the&nbsp; safety&nbsp; and&nbsp; efficacy&nbsp; of&nbsp; linezolid&nbsp; in&nbsp; children&nbsp; and&nbsp; adolescents (&lt; 18 years old) to establish dosage recommendations (see sections 5.1 and 5.2). Therefore, until further data are available, use of linezolid in this age group is not recommended.</p><p style="text-align:justify"><em><u>Elderly patients:</u></em></p><p style="text-align:justify">No dose adjustment is required.</p><p style="text-align:justify"><em><u>Patients with renal insufficiency:</u></em></p><p style="text-align:justify">No dose adjustment is required (see sections 4.4 and 5.2).</p><p style="text-align:justify"><em><u>Patients with severe renal insufficiency (i.e. CL<sub>CR</sub> &lt; 30 ml/min):</u></em></p><p style="text-align:justify">No dose adjustment is required. Due to the unknown clinical significance of higher exposure (up to 10 fold) to the two primary metabolites of linezolid in patients with severe renal insufficiency, linezolid should be used with special caution in these patients and only when the anticipated benefit is considered to outweigh the theoretical risk.</p><p style="text-align:justify">As approximately 30% of a linezolid dose is removed during 3 hours of haemodialysis, linezolid should be given after dialysis in patients receiving such treatment. The primary metabolites of linezolid are removed to some extent by haemodialysis, but the concentrations of these metabolites are still very considerably higher following dialysis than those observed in patients with normal renal function or mild to moderate renal insufficiency.</p><p style="text-align:justify">Therefore, linezolid should be used with special caution in patients with severe renal insufficiency who are undergoing dialysis and only when the anticipated benefit is considered to outweigh the theoretical risk.</p><p style="text-align:justify">To date, there is no experience of linezolid administration to patients undergoing continuous ambulatory peritoneal dialysis (CAPD) or alternative treatments for renal failure (other than haemodialysis).</p><p style="text-align:justify"><em><u>Patients with hepatic insufficiency</u>:</em></p><p style="text-align:justify">No dose adjustment is required. However, there are limited clinical data and it is recommended that linezolid should be used in such patients only when the anticipated benefit is considered to outweigh the theoretical risk (see sections 4.4 and 5.2).</p><p style="text-align:justify"><u>Method of administration:</u></p><p style="text-align:justify">The recommended linezolid dosage should be administered intravenously twice daily.</p><p style="text-align:justify">Route of administration: Intravenous use.</p><p style="text-align:justify">The solution for infusion should be administered over a period of 30 to 120 minutes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Linezolid should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g. phenelzine, isocarboxazid, selegiline, moclobemide) or within two weeks of taking any such medicinal product.
Unless there are facilities available for close observation and monitoring of blood pressure, linezolid should not be administered to patients with the following underlying clinical conditions or on the following types of concomitant medications:
-	Patients with uncontrolled hypertension, phaeochromocytoma, carcinoid, thyrotoxicosis, bipolar depression, schizoaffective disorder, acute confusional states.
-	Patients taking any of the following medications: serotonin re-uptake inhibitors (see section 4.4), tricyclic antidepressants, serotonin 5 HT1 receptor agonists (triptans), directly and indirectly acting sympathomimetic agents (including the adrenergic bronchodilators, pseudoephedrine and phenylpropanolamine), vasopressive agents (e.g. adrenaline and noradrenaline), dopaminergic agents (e.g. dopamine, dobutamine), pethidine or buspirone.
Animal data suggest that linezolid and its metabolites may pass into breast milk and, accordingly, breastfeeding should be discontinued prior to and throughout administration (see section 4.6).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><em><u>Myelosuppression</u></em></p><p style="text-align:justify">Myelosuppression (including anaemia, leucopenia, pancytopenia and thrombocytopenia) has been reported in patients receiving linezolid. In cases where the outcome is known, when linezolid was discontinued, the affected haematologic parameters have risen toward pretreatment levels. The risk of these effects appears to be related to the duration of treatment. Elderly patients treated with linezolid may be at greater risk of experiencing blood dyscrasias than younger patients. Thrombocytopenia may occur more commonly in patients with severe renal insufficiency, whether&nbsp; or not on dialysis. Therefore, close monitoring of blood counts is recommended in patients who: have pre-existing anaemia, granulocytopenia or thrombocytopenia; are receiving concomitant medications that may decrease haemoglobin levels, depress blood counts or adversely affect platelet count or function; have severe renal insufficiency; receive more than 10-14 days of therapy. Linezolid should be administered to such patients only when close monitoring of haemoglobin levels, blood counts and platelet counts is possible.</p><p style="text-align:justify">If significant myelosuppression occurs during linezolid therapy, treatment should be stopped unless it is considered absolutely necessary to continue therapy, in which case intensive monitoring of blood counts and appropriate management strategies should be implemented.</p><p style="text-align:justify">In addition, it is recommended that complete blood counts (including haemoglobin levels, platelets, and total and differentiated leucocyte counts) should be monitored <u>weekly</u> in patients who receive linezolid regardless of baseline blood count.</p><p style="text-align:justify">In compassionate use studies, a higher incidence of serious anaemia was reported in patients receiving linezolid for more than the maximum recommended duration of 28 days. These patients more often required blood transfusion. Cases of anaemia requiring blood transfusion have also been reported post marketing, with more cases occurring in patients who received linezolid therapy for more than 28 days.</p><p style="text-align:justify">Cases of sideroblastic anaemia have been reported post-marketing. Where time of onset was known, most patients had received linezolid therapy for more than 28 days. Most patients fully or partially recovered following discontinuation of linezolid with or without treatment for their anaemia.</p><p style="text-align:justify"><em><u>Mortality imbalance in a clinical trial in patients with catheter-related Gram positive bloodstream</u> <u>infections</u></em></p><p style="text-align:justify">Excess mortality was seen in patients treated with linezolid, relative to vancomycin/dicloxacillin/oxacillin, in an open-label study in seriously ill patients with intravascular catheter-related infections [78/363 (21.5%) vs 58/363 (16.0%)]. The main factor influencing the mortality rate was the Gram positive infection status at baseline. Mortality rates were similar in patients with infections caused purely by Gram positive organisms (odds ratio 0.96; 95% confidence interval: 0.58-1.59) but were significantly higher (p=0.0162) in the linezolid arm in patients with any other pathogen or no pathogen at baseline (odds ratio 2.48; 95% confidence interval: 1.38-4.46). The greatest imbalance occurred during treatment and within 7 days following discontinuation of study drug. More patients in the linezolid arm acquired Gram negative pathogens during the study and died from infection caused by Gram negative pathogens and polymicrobial infections. Therefore, in complicated skin and soft tissue infections linezolid should only be used in patients with known or possible co-infection with Gram negative organisms if there are no alternative treatment options available (see section 4.1). In these circumstances treatment against Gram negative organisms <u>must</u> be initiated concomitantly.</p><p style="text-align:justify"><em><u>Antibiotic-associated diarrhoea and colitis</u></em></p><p style="text-align:justify">Pseudomembranous colitis has been reported with nearly all antibacterial agents, including linezolid. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea subsequent to the administration of any antibacterial agent. In cases of suspected or verified antibiotic-associated colitis, discontinuation of linezolid may be warranted. Appropriate management measures should be instituted.</p><p style="text-align:justify">Antibiotic-associated diarrhoea and antibiotic-associated colitis, including pseudomembranous&nbsp; colitis and <em>Clostridium difficile</em>-associated diarrhoea, has been reported in association with the use of nearly all antibiotics including linezolid and may range in severity from mild diarrhoea to fatal colitis. Therefore, it is important to consider this diagnosis in patients who develop serious diarrhoea during or after the use of linezolid. If antibiotic-associated diarrhoea or antibiotic-associated colitis is suspected or confirmed, ongoing treatment with antibacterial agents, including linezolid, should be discontinued and adequate therapeutic measures should be initiated immediately. Drugs inhibiting peristalsis are contraindicated in this situation.</p><p style="text-align:justify"><em><u>Lactic acidosis</u></em></p><p style="text-align:justify">Lactic acidosis has been reported with the use of linezolid. Patients who develop signs and&nbsp; symptoms of metabolic acidosis including recurrent nausea or vomiting, abdominal pain, a low bicarbonate level, or hyperventilation while receiving linezolid should receive immediate medical attention. If lactic acidosis occurs, the benefits of continued use of linezolid should be weighed against the potential risks.</p><p style="text-align:justify"><em><u>Mitochondrial dysfunction</u></em></p><p style="text-align:justify">Linezolid inhibits mitochondrial protein synthesis. Adverse events, such as lactic acidosis, anaemia and neuropathy (optic and peripheral), may occur as a result of this inhibition; these events are more common when the drug is used longer than 28 days.</p><p style="text-align:justify"><em><u>Serotonin syndrome</u></em></p><p style="text-align:justify">Spontaneous reports of serotonin syndrome associated with the co-administration of linezolid and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs) have been reported. Co-administration of linezolid and serotonergic agents is therefore contraindicated (see section 4.3) except where administration of linezolid and concomitant serotonergic agents is essential. In those cases patients should be closely observed for signs and symptoms of serotonin syndrome such as cognitive dysfunction, hyperpyrexia, hyperreflexia and incoordination. If signs or symptoms occur physicians should consider discontinuing either one or both agents; if the concomitant serotonergic agent is withdrawn, discontinuation symptoms can occur.</p><p style="text-align:justify"><em><u>Peripheral and optic neuropathy</u></em></p><p style="text-align:justify">Peripheral neuropathy, as well as optic neuropathy and optic neuritis sometimes progressing to loss of vision, have been reported in patients treated with linezolid; these reports have primarily been in patients treated for longer than the maximum recommended duration of 28 days.</p><p style="text-align:justify">All patients should be advised to report symptoms of visual impairment, such as changes in visual acuity, changes in colour vision, blurred vision, or visual field defect. In such cases, prompt evaluation is recommended with referral to an ophthalmologist as necessary. If any patients are taking Linezolid for longer than the recommended 28 days, their visual function should be regularly monitored.</p><p style="text-align:justify">If peripheral or optic neuropathy occurs, the continued use of &lt;Linezolid should be weighed against the potential risks.</p><p style="text-align:justify">There may be an increased risk of neuropathies when linezolid is used in patients currently taking or who have recently taken antimycobacterial medications for the treatment of tuberculosis.</p><p style="text-align:justify"><em><u>Convulsions</u></em></p><p style="text-align:justify">Convulsions have been reported to occur in patients when treated with Linezolid. In most of these cases, a history of seizures or risk factors for seizures was reported. Patients should be advised to inform their physician if they have a history of seizures.</p><p style="text-align:justify"><em><u>Monoamine oxidase inhibitors</u></em></p><p style="text-align:justify">Linezolid is a reversible, non-selective inhibitor of monoamine oxidase (MAOI); however, at the doses used for antibacterial therapy, it does not exert an anti-depressive effect. There are very limited data from drug interaction studies and on the safety of linezolid when administered to patients with underlying conditions and/or on concomitant medications which might put them at risk from MAO inhibition. Therefore, linezolid is not recommended for use in these circumstances unless close observation and monitoring of the recipient is possible (see sections 4.3 and 4.5).</p><p style="text-align:justify"><em><u>Use with tyramine-rich foods</u></em></p><p style="text-align:justify">Patients should be advised against consuming large amounts of tyramine rich foods (see section 4.5).</p><p style="text-align:justify"><em><u>Superinfection</u></em></p><p style="text-align:justify">The effects of linezolid therapy on normal flora have not been evaluated in clinical trials.</p><p style="text-align:justify">The use of antibiotics may occasionally result in an overgrowth of non-susceptible organisms. For example, approximately 3% of patients receiving the recommended linezolid doses experienced drug-related candidiasis during clinical trials. Should superinfection occur during therapy, appropriate measures should be taken.</p><p style="text-align:justify"><em><u>Special populations</u></em></p><p style="text-align:justify">Linezolid should be used with special caution in patients with severe renal insufficiency and only when the anticipated benefit is considered to outweigh the theoretical risk (see sections 4.2 and 5.2).</p><p style="text-align:justify">It is recommended that linezolid should be given to patients with severe hepatic insufficiency only when the perceived benefit outweighs the theoretical risk (see sections 4.2 and 5.2).</p><p style="text-align:justify"><em><u>Clinical trials</u></em></p><p style="text-align:justify">The safety and effectiveness of linezolid when administered for periods longer than 28 days have not been established.</p><p style="text-align:justify">Controlled clinical trials did not include patients with diabetic foot lesions, decubitus or ischaemic lesions, severe burns or gangrene. Therefore, experience in the use of linezolid in the treatment of these conditions is limited.</p><p style="text-align:justify"><em><u>Excipients</u></em></p><p style="text-align:justify">Each ml of the solution contains 45.7 mg (i.e. 13.7 g/300 ml) glucose. This should be taken into account in patients with diabetes mellitus or other conditions associated with glucose intolerance. Each ml of solution also contains 0.38 mg (114 mg/300 ml) sodium. The sodium content should be taken into account in patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><em><u>Monoamine oxidase inhibitors</u></em></p><p style="text-align:justify">Linezolid is a reversible, non-selective inhibitor of monoamine oxidase (MAOI). There are very limited data from drug interaction studies and on the safety of linezolid when administered to patients on concomitant medications that might put them at risk from MAO inhibition. Therefore, linezolid is not recommended for use in these circumstances unless close observation and monitoring of the recipient is possible (see sections 4.3 and 4.4).</p><p style="text-align:justify"><em><u>Potential interactions producing elevation of blood pressure</u></em></p><p style="text-align:justify">In normotensive healthy volunteers, linezolid enhanced the increases in blood pressure caused by pseudoephedrine and phenylpropanolamine hydrochloride. Co-administration of linezolid with either pseudoephedrine or phenylpropanolamine resulted in mean increases in systolic blood pressure of&nbsp; the order of 30-40 mmHg, compared with 11-15 mmHg increases with linezolid alone, 14-18 mmHg with either pseudoephedrine or phenylpropanolamine alone and 8-11 mmHg with placebo. Similar studies in hypertensive subjects have not been conducted. It is recommended that doses of drugs with a vasopressive action, including dopaminergic agents, should be carefully titrated to achieve the desired response when co-administered with linezolid.</p><p style="text-align:justify"><em><u>Potential serotonergic interactions</u></em></p><p style="text-align:justify">The potential drug-drug interaction with dextromethorphan was studied in healthy volunteers. Subjects were administered dextromethorphan (two 20 mg doses given 4 hours apart) with&nbsp; or without linezolid. No serotonin syndrome effects (confusion, delirium, restlessness, tremors, blushing, diaphoresis, hyperpyrexia) have been observed in normal subjects receiving linezolid and dextromethorphan.</p><p style="text-align:justify">Post marketing experience: there has been one report of a patient experiencing serotonin syndrome- like effects while taking linezolid and dextromethorphan which resolved on discontinuation of both medications.</p><p style="text-align:justify">During clinical use of linezolid with serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), cases of serotonin syndrome have been reported. Therefore, while co-administration is contraindicated (see section 4.3), management of patients for whom treatment with linezolid and serotonergic agents is essential, is described in section 4.4.</p><p style="text-align:justify"><em><u>Use with tyramine-rich foods</u></em></p><p style="text-align:justify">No significant pressor response was observed in subjects receiving both linezolid and less than 100 mg tyramine. This suggests that it is only necessary to avoid ingesting excessive amounts of food and beverages with a high tyramine content (e.g. mature cheese, yeast extracts, undistilled alcoholic beverages and fermented soya bean products such as soy sauce).</p><p style="text-align:justify"><em><u>Drugs metabolised by cytochrome P450</u></em></p><p style="text-align:justify">Linezolid is not detectably metabolised by the cytochrome P450 (CYP) enzyme system and it does not inhibit any of the clinically significant human CYP isoforms (1A2, 2C9, 2C19, 2D6, 2E1, 3A4). Similarly, linezolid does not induce P450 isoenzymes in rats. Therefore, no CYP450-induced drug interactions are expected with linezolid</p><p style="text-align:justify"><em><u>Rifampicin</u></em></p><p style="text-align:justify">The effect of rifampicin on the pharmacokinetics of linezolid was studied in sixteen healthy adult male volunteers administered linezolid 600 mg twice daily for 2.5 days with and without rifampicin 600 mg once daily for 8 days. Rifampicin decreased the linezolid Cmax and AUC by a mean 21% [90% confidence interval: 15-27] and a mean 32% [90% confidence interval: 27-37], respectively. The mechanism of this interaction and its clinical significance are unknown.</p><p style="text-align:justify"><em><u>Warfarin</u></em></p><p style="text-align:justify">When warfarin was added to linezolid therapy at steady-state, there was a 10% reduction in mean maximum INR on co-administration with a 5% reduction in AUC INR. There are insufficient data from patients who have received warfarin and linezolid to assess the clinical significance, if any, of these findings.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Pregnancy</u></p><p style="text-align:justify">There are no adequate data from the use of linezolid in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). A potential risk for humans exists.</p><p style="text-align:justify">Linezolid should not be used during pregnancy unless clearly necessary i.e. only if the potential benefit outweighs the theoretical risk.</p><p style="text-align:justify"><u>Breast-feeding</u></p><p style="text-align:justify">Animal data suggest that linezolid and its metabolites may pass into breast milk and, accordingly, breastfeeding should be discontinued prior to and throughout administration.</p><p style="text-align:justify"><u>Fertility</u></p><p style="text-align:justify">In animal studies, linezolid caused a reduction in fertility (see section 5.3). It is not known whether these findings have an impact on human fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Patients should be warned about the potential for dizziness or symptoms of visual impairment (as described in section 4.4 and 4.8) whilst receiving linezolid and should be advised not to drive or operate machinery if any of these symptoms occurs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">The table below provides a listing of adverse drug reactions with frequency based on all-causality data from clinical studies that enrolled more than 2,000 adult patients who received the recommended linezolid doses for up to 28 days.</p><p style="text-align:justify">Those most commonly reported were diarrhoea (8.4%), headache (6.5%), nausea (6.3%) and vomiting (4.0%).</p><p style="text-align:justify">The most commonly reported drug-related adverse events which led to discontinuation of treatment were headache, diarrhoea, nausea and vomiting. About 3% of patients discontinued treatment because they experienced a drug-related adverse event.</p><p style="text-align:justify">Additional adverse reactions reported from post-marketing experience are included in the table with frequency category &#39;Not known&#39;, since the actual frequency cannot be estimated from the available data.</p><p style="text-align:justify">The following undesirable effects have been observed and reported during treatment with linezolid with the following frequencies: Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); Not known (cannot be estimated from the available data)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p style="text-align:justify"><strong>Common</strong></p><p style="text-align:justify"><strong>(&ge;1/100 to</strong></p><p style="text-align:justify"><strong>&lt;1/10)</strong></p></td><td style="vertical-align:top"><p style="text-align:justify"><strong>Uncommon</strong></p><p style="text-align:justify"><strong>(&ge;1/1,000 to</strong></p><p style="text-align:justify"><strong>&lt;1/100)</strong></p></td><td style="vertical-align:top"><p style="text-align:justify"><strong>Rare</strong></p><p style="text-align:justify"><strong>(&ge;1/10,000 to</strong></p><p style="text-align:justify"><strong>&lt;1/1,000)</strong></p></td><td style="vertical-align:top"><p style="text-align:justify"><strong>Frequency not known (cannot be estimated from</strong></p><p style="text-align:justify"><strong>available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p style="text-align:justify">candidiasis, oral candidiasis, vaginal candidiasis, fungal</p><p style="text-align:justify">infections</p></td><td style="vertical-align:top"><p style="text-align:justify">vaginitis</p></td><td style="vertical-align:top"><p style="text-align:justify">Antibioticassociate d colitis,</p><p style="text-align:justify">including pseudomembranou s colitis*</p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>Blood and the lymphatic system</strong></p><p style="text-align:justify"><strong>disorders</strong></p></td><td style="vertical-align:top"><p style="text-align:justify">anaemia*&dagger;</p></td><td style="vertical-align:top"><p style="text-align:justify">Leucopenia*, neutropenia, thrombocytopenia</p><p style="text-align:justify">*, eosinophilia</p></td><td style="vertical-align:top"><p style="text-align:justify">pancytopenia*</p></td><td style="vertical-align:top"><p style="text-align:justify">Myelosuppression</p><p style="text-align:justify">*, sideroblastic anaemia*</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">Anaphylaxis</p></td></tr><tr><td style="vertical-align:top"><strong>Metabolism and nutrition disorders</strong></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">hyponatraemia</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">Lactic acidosis*</td></tr><tr><td style="vertical-align:top"><strong>Psychiatric </strong><strong>disorders</strong></td><td style="vertical-align:top">Insomnia</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><strong>Nervous system disorders</strong></td><td style="vertical-align:top">Headache, taste perversion (metallic taste), dizziness</td><td style="vertical-align:top">convulsions*, hypoaesthesia, paraesthesia</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">Serotonin syndrome**, , peripheral neuropathy*</td></tr><tr><td style="vertical-align:top"><strong>Eye disorders</strong></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">Blurred vision*</td><td style="vertical-align:top">changes in visual field defect*</td><td style="vertical-align:top"><p style="text-align:justify">Optic neuropathy*, optic neuritis*, loss of vision*, changes in visual acuity*, changes in colour vision*</p></td></tr><tr><td style="vertical-align:top"><strong>Ear and labyrinth disorders</strong></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">Tinnitus</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><strong>Cardiac disorders</strong></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">Arrhythmia (tachycardia)</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><strong>Vascular disorders</strong></td><td style="vertical-align:top">Hypertension</td><td style="vertical-align:top">Transient ischaemic attacks, phlebitis, thrombophlebitis</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><strong>Gastrointestin</strong><strong>al disorders</strong></td><td style="vertical-align:top">Diarrhoea, nausea, vomiting, localised or general abdominal pain, constipation, dyspepsia</td><td style="vertical-align:top">Pancreatitis, gastritis, abdominal Distention, dry mouth, glossitis, loose stools, stomatitis, tongue discolouration or disorder</td><td style="vertical-align:top">Superficial tooth discolouration</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><strong>Hepato-biliary disorders</strong></td><td style="vertical-align:top">Abnormal liver function test; increased AST, ALT or alkaline phosphatase</td><td style="vertical-align:top">Increased total bilirubin</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><strong>Skin and subcutaneous tissue disorders</strong></td><td style="vertical-align:top">pruritus, rash</td><td style="vertical-align:top">Urticaria, dermatitis, diaphoresis,</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">Bullous disorders such as those described as Stevens-Johnson syndrome and toxic epidermal&nbsp;necrolysis, angioedema, alopecia</td></tr><tr><td style="vertical-align:top"><strong>Renal and urinary disorders</strong></td><td style="vertical-align:top">Increased BUN</td><td style="vertical-align:top">Renal failure, polyuria, increased creatinine</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><strong>Reproductivesystem and&nbsp;breast&nbsp;disorders</strong></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">Vulvovaginal&nbsp;disorder</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><strong>General&nbsp;disorders and&nbsp;administration&nbsp;site conditions</strong></td><td style="vertical-align:top">fever,localised pain</td><td style="vertical-align:top"><p>Chills, fatigue, injection site pain,&nbsp;<span style="background-color:transparent">increased thirst</span></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><strong>Investigations</strong></td><td style="vertical-align:top"><p><u>Chemistry</u> Increased LDH, creatine kinase, lipase, amylase or non fasting glucose.</p><p>Decreased total protein, albumin, sodium or calcium.</p><p>Increased or decreased potassium or bicarbonate.</p><p><u>Haematolog</u> <u>y</u></p><p>Increased neutrophils or eosinophils. Decreased haemoglobin, haematocrit or red blood cell count. Increased or decreased platelet or white blood&nbsp;<span style="background-color:transparent">cell counts</span></p></td><td style="vertical-align:top"><p><u>Chemistry</u> Increased sodium or calcium.</p><p>Decreased non fasting glucose. Increased or decreased chloride.</p><u>Haematology</u> Increased reticulocyte count. Decreased neutrophils.</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p style="text-align:justify">*&nbsp; See section 4.4.</p><p style="text-align:justify">** See sections 4.3 and 4.5</p><p style="text-align:justify">&dagger; See below</p><p style="text-align:justify">The following adverse reactions to linezolid were considered to be serious in rare cases: localised abdominal pain, transient ischaemic attacks and hypertension.</p><p style="text-align:justify">&dagger; In controlled clinical trials where linezolid was administered for up to 28 days, 2.0 % of the patients reported anaemia. In a compassionate use program of patients with life-threatening infections and underlying co-morbidities, the percentage of patients who developed anaemia when receiving linezolid for &le; 28 days was 2.5% (33/1326) as compared with 12.3% (53/430) when treated for &gt;28 days. The proportion of cases reporting drug-related serious anaemia and requiring blood transfusion was 9% (3/33) in patients treated for &le; 28 days and 15% (8/53) in those treated for &gt;28 days.</p><p style="text-align:justify"><em>Paediatric population</em></p><p style="text-align:justify">Safety data from clinical studies based on more than 500 paediatric patients (from birth to 17 years) do not indicate that the safety profile of linezolid for paediatric patients differs from that for adult patients.</p><p style="text-align:justify"><u>Reporting of suspected adverse reactions</u></p><p style="text-align:justify">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in <u>Appendix V</u>.</p><p>To report any side effect(s):</p><ul><li><strong>Saudi Arabia:</strong><ul><li>The National Pharmacovigilance Centre (NPC)<ul><li>Fax: +966-11-205-7662</li><li>SFDA Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa&nbsp;</li></ul></li></ul></li><li><strong>Other GCC States:</strong><br />Please contact the relevant competent authority.</li></ul><p style="text-align:justify">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">No specific antidote is known.</p><p style="text-align:justify">No cases of overdose have been reported. However, the following information may prove useful:</p><p style="text-align:justify">Supportive care is advised together with maintenance of glomerular filtration. Approximately 30% of a linezolid dose is removed during 3 hours of haemodialysis, but no data are available for the removal of linezolid by peritoneal dialysis or haemoperfusion. The two primary metabolites of linezolid are also removed to some extent by haemodialysis.</p><p style="text-align:justify">Signs of toxicity in rats following doses of 3000 mg/kg/day linezolid were decreased activity and ataxia whilst dogs treated with 2000 mg/kg/day experienced vomiting and tremors.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Pharmacotherapeutic group: Other antibacterials. ATC code: J01X X08</p><p style="text-align:justify"><u>General Properties</u></p><p style="text-align:justify">Linezolid is a synthetic, antibacterial agent that belongs to a new class of antimicrobials, the oxazolidinones. It has in vitro activity against aerobic Gram positive bacteria and anaerobic micro- organisms. Linezolid selectively inhibits bacterial protein synthesis via a unique mechanism of action.</p><p style="text-align:justify">Specifically, it binds to a site on the bacterial ribosome (23S of the 50S subunit) and prevents the formation of a functional 70S initiation complex which is an essential component of the translation process.</p><p style="text-align:justify">The in vitro postantibiotic effect (PAE) of linezolid for <em>Staphylococcus aureus </em>was approximately 2 hours. When measured in animal models, the in vivo PAE was 3.6 and 3.9 hours for <em>Staphylococcus aureus </em>and <em>Streptococcus pneumoniae, </em>respectively. In animal studies, the key pharmacodynamic parameter for efficacy was the time for which the linezolid plasma level exceeded the minimum inhibitory concentration (MIC) for the infecting organism.</p><p style="text-align:justify"><u>Breakpoints</u></p><p style="text-align:justify">Minimum inhibitory concentration (MIC) breakpoints established by the &ldquo;European Committee on Antimicrobial Susceptibility Testing&rdquo; (EUCAST) for staphylococci and enterococci are Susceptible</p><p style="text-align:justify">&le;4mg/L and Resistant &gt;4 mg/L. For streptococci (including <em>S. pneumoniae</em>) the breakpoints are</p><p style="text-align:justify">Susceptible &le;2 mg/L and Resistant &gt;4 mg/L. Non-species related MIC breakpoints are Susceptible</p><p style="text-align:justify">&le;2 mg/L and Resistant &gt;4 mg/L. Non-species related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for organisms that have not been given a specific breakpoint and not for those species where susceptibility testing is not recommended.</p><p style="text-align:justify"><u>Susceptibility</u></p><p style="text-align:justify">The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Category</strong></p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify"><u>Susceptible organisms</u></p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Gram positive aerobes:&nbsp;</strong></p><p style="text-align:justify"><em>Enterococcus faecalis Enterococcus faecium* Staphylococcus aureus* </em>Coagulase negative staphylococci <em>Streptococcus agalactiae* Streptococcus pneumoniae* Streptococcus pyogenes*</em></p><p style="text-align:justify">Group C streptococci Group G streptococci</p><p style="text-align:justify"><strong>Gram positive anaerobes: </strong><em>Clostridium perfringens Peptostreptococcus anaerobius Peptostreptococcus </em>species</p></td><td style="vertical-align:top"><p style="text-align:justify"><u>Resistant organisms</u></p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Haemophilus influenzae&nbsp;Moraxella catarrhalis Neisseria </em>species <em>Enterobacteriaceae Pseudomonas </em>species</p></td></tr></tbody></table><p style="text-align:justify">*Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications.</p><p style="text-align:justify">Whereas linezolid shows some in vitro activity against <em>Legionella, Chlamydia pneumoniae </em>and</p><p style="text-align:justify"><em>Mycoplasma pneumoniae, </em>there are insufficient data to demonstrate clinical efficacy.</p><p style="text-align:justify"><em><u>Resistance</u></em></p><p style="text-align:justify"><u>Cross resistance</u></p><p style="text-align:justify">Linezolid&#39;s mechanism of action differs from those of other antibiotic classes. In vitro studies with clinical isolates (including methicillin-resistant staphylococci, vancomycin-resistant enterococci, and penicillin- and erythromycin-resistant streptococci) indicate that linezolid is usually active against organisms which are resistant to one or more other classes of antimicrobial agents.</p><p style="text-align:justify">Resistance to linezolid is associated with point mutations in the 23S rRNA.</p><p style="text-align:justify">As documented with other antibiotics when used in patients with difficult to treat infections and/or for prolonged periods, emergent decreases in susceptibility have been observed with linezolid. Resistance to linezolid has been reported in enterococci, <em>Staphylococcus aureus </em>and coagulase negative staphylococci. This generally has been associated with prolonged courses of therapy and the presence of prosthetic materials or undrained abscesses. When antibiotic-resistant organisms are encountered in the hospital it is important to emphasize infection control policies.</p><p style="text-align:justify"><em><u>Information from clinical trials</u></em></p><p style="text-align:justify">Studies in the paediatric population:</p><p style="text-align:justify">In an open study, the efficacy of linezolid (10 mg/kg q8h) was compared to vancomycin (10- 15mg/kg q6-24h) in treating infections due to suspected or proven resistant gram-positive pathogens (including nosocomial pneumonia, complicated skin and skin structure infections, catheter related bacteraemia, bacteraemia of unknown source, and other infections), in children from birth to 11 years. Clinical cure rates in the clinically evaluable population were 89.3% (134/150) and 84.5% (60/71) for linezolid and vancomycin, respectively (95%CI: -4.9, 14.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">LINID primarily contains (s)-linezolid which is biologically active and is metabolised to form inactive derivatives.</p><p style="text-align:justify"><em><u>Absorption</u></em></p><p style="text-align:justify">Linezolid is rapidly and extensively absorbed following oral dosing. Maximum plasma concentrations are reached within 2 hours of dosing. Absolute oral bioavailability of linezolid (oral and intravenous dosing in a crossover study) is complete (approximately 100%).Absorption is not significantly affected by food and absorption from the oral suspension is similar to that achieved with the film-coated tablets.</p><p style="text-align:justify">Plasma linezolid C<sub>max</sub> and C<sub>min</sub> (mean and [SD]) at steady-state following twice daily intravenous dosing of 600 mg have been determined to be 15.1 [2.5] mg/l and 3.68 [2.68] mg/l, respectively.&nbsp;</p><p style="text-align:justify">In another study following oral dosing of 600 mg twice daily to steady-state, C<sub>max</sub> and C<sub>min</sub> were determined to be 21.2 [5.8] mg/l and 6.15 [2.94] mg/l, respectively. Steady-state conditions are achieved by the second day of dosing.</p><p style="text-align:justify"><em><u>Distribution</u></em></p><p style="text-align:justify">Volume of distribution at steady-state averages at about 40-50 litres in healthy adults and approximates to total body water. Plasma protein binding is about 31% and is not concentration dependent.</p><p style="text-align:justify">Linezolid concentrations have been determined in various fluids from a limited number of subjects in volunteer studies following multiple dosing. The ratio of linezolid in saliva and sweat relative to plasma was 1.2:1.0 and 0.55:1.0, respectively. The ratio for epithelial lining fluid and alveolar cells of the lung was 4.5:1.0 and 0.15:1.0, when measured at steady-state C<sub>max</sub>, respectively. In a small study of subjects with ventricular-peritoneal shunts and essentially non-inflamed meninges, the ratio of linezolid in cerebrospinal fluid to plasma at C<sub>max</sub> was 0.7:1.0 after multiple linezolid dosing.</p><p style="text-align:justify"><em><u>Biotransformation</u></em></p><p style="text-align:justify">Linezolid is primarily metabolised by oxidation of the morpholine ring resulting mainly in the formation of two inactive open-ring carboxylic acid derivatives; the aminoethoxyacetic acid metabolite (PNU-142300) and the hydroxyethyl glycine metabolite (PNU-142586). The hydroxyethyl glycine metabolite (PNU-142586) is the predominant human metabolite and is believed to be formed by a non-enzymatic process. The aminoethoxyacetic acid metabolite (PNU- 142300) is less abundant. Other minor, inactive metabolites have been characterised.</p><p style="text-align:justify"><em><u>Elimination</u></em></p><p style="text-align:justify">In patients with normal renal function or mild to moderate renal insufficiency, linezolid is primarily excreted under steady-state conditions in the urine as PNU-142586 (40%), parent drug (30%) and PNU-142300 (10%). Virtually no parent drug is found in the faeces whilst approximately 6% and&nbsp; 3% of each dose appears as PNU-142586 and PNU-142300, respectively.</p><p style="text-align:justify">The elimination half-life of linezolid averages at about 5-7 hours.</p><p style="text-align:justify">Non-renal clearance accounts for approximately 65% of the total clearance of linezolid. A small degree of non-linearity in clearance is observed with increasing doses of linezolid.</p><p style="text-align:justify">This appears to be due to lower renal and non-renal clearance at higher linezolid concentrations. However, the difference in clearance is small and is not reflected in the apparent elimination half- life.</p><p style="text-align:justify"><em><u>Special Populations</u></em></p><p style="text-align:justify"><u>Patients with renal insufficiency:</u> After single doses of 600 mg, there was a 7-8 fold increase in exposure to the two primary metabolites of linezolid in the plasma of patients with severe renal insufficiency (i.e. creatinine clearance &lt; 30 ml/min). However, there was no increase in AUC of parent drug. Although there is some removal of the major metabolites of linezolid by haemodialysis, metabolite plasma levels after single 600 mg doses were still considerably higher following dialysis than those observed in patients with normal renal function or mild to moderate renal insufficiency.</p><p style="text-align:justify">In 24 patients with severe renal insufficiency, 21 of whom were on regular haemodialysis, peak plasma concentrations of the two major metabolites after several days dosing were about 10 fold those seen in patients with normal renal function. Peak plasma levels of linezolid were not affected.</p><p style="text-align:justify">The clinical significance of these observations has not been established as limited safety data are currently available (see sections 4.2 and 4.4).</p><p style="text-align:justify"><u>Patients with hepatic insufficiency:</u> Limited data indicate that the pharmacokinetics of linezolid, PNU-142300 and PNU-142586 are not altered in patients with mild to moderate hepatic insufficiency (i.e. Child-Pugh class A or B). The pharmacokinetics of linezolid in patients with severe hepatic insufficiency (i.e. Child-Pugh class C) have not been evaluated. However, as linezolid is metabolised by a non-enzymatic process, impairment of hepatic function would not be expected to significantly alter its metabolism (see sections 4.2 and 4.4).</p><p style="text-align:justify"><u>Paediatric population (&lt;18 years old):</u> There are insufficient data on the safety and efficacy of linezolid in children and adolescents (&lt;18 years old) and therefore, use of linezolid in this age group is not recommended (see section 4.2). Further studies are needed to establish safe and effective dosage recommendations. Pharmacokinetic studies indicate that after single and multiple doses in children (1 week to 12 years), linezolid clearance (based on kg body weight) was greater in paediatric patients than in adults, but decreased with increasing age.</p><p style="text-align:justify">In children 1 week to 12 years old, administration of 10 mg/kg every 8 hours daily gave exposure approximating to that achieved with 600 mg twice daily in adults.</p><p style="text-align:justify">In neonates up to 1 week of age, the systemic clearance of linezolid (based on kg body weight) increases rapidly in the first week of life.</p><p style="text-align:justify">Therefore, neonates given 10 mg/kg every 8 hours daily will have the greatest systemic exposure on the first day after delivery.</p><p style="text-align:justify">However, excessive accumulation is not expected with this dosage regimen during the first week of life as clearance increases rapidly over that period.</p><p style="text-align:justify">In adolescents (12 to 17 years old), linezolid pharmacokinetics were similar to that in adults following a 600mg dose. Therefore, adolescents administered 600 mg every 12 hours daily will have similar exposure to that observed in adults receiving the same dosage.</p><p style="text-align:justify">In paediatric patients with ventriculoperitoneal shunts who were administered linezolid 10mg/kg either 12 hourly or 8 hourly, variable cerebrospinal fluid (CSF) linezolid concentrations were observed following either single or multiple dosing of linezolid. Therapeutic concentrations were not consistently achieved or maintained in the CSF. Therefore, the use of linezolid for the empirical treatment of paediatric patients with central nervous system infections is not recommended.</p><p style="text-align:justify"><u>Elderly patients:</u> The pharmacokinetics of linezolid are not significantly altered in elderly patients aged 65 and over.</p><p style="text-align:justify"><u>Female patients:</u> Females have a slightly lower volume of distribution than males and the mean clearance is reduced by approximately 20% when corrected for body weight. Plasma concentrations are higher in females and this can partly be attributed to body weight differences. However, because the mean half life of linezolid is not significantly different in males and females, plasma concentrations in females are not expected to substantially rise above those known to be well tolerated and, therefore, dose adjustments are not required.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Linezolid decreased fertility and reproductive performance of male rats at exposure levels approximately equal to those expected in humans. In sexually mature animals these effects were reversible. However, these effects did not reverse in juvenile animals treated with linezolid for nearly the entire period of sexual maturation. Abnormal sperm morphology in testis of adult male rats, and epithelial cell hypertrophy and hyperplasia in the epididymis were noted. Linezolid appeared to affect the maturation of rat spermatozoa. Supplementation of testosterone had no effect on linezolid- mediated fertility effects. Epididymal hypertrophy was not observed in dogs treated for 1 month, although changes in the weights of prostate, testes and epididymis were apparent.</p><p style="text-align:justify">Reproductive toxicity studies in mice and rats showed no evidence of a teratogenic effect at exposure levels 4 times or equivalent, respectively, to those expected in humans.</p><p style="text-align:justify">The same linezolid concentrations caused maternal toxicity in mice and were related to increased embryo death including total litter loss, decreased fetal body weight and an exacerbation of the normal genetic predisposition to sternal variations in the strain of mice. In rats, slight maternal toxicity was noted at exposures lower than expected clinical exposures.</p><p style="text-align:justify">Mild fetal toxicity, manifested as decreased fetal body weights, reduced ossification of sternebrae (sternum and vertebrae), reduced pup survival and mild maturational delays were noted. When mated, these same pups showed evidence of a reversible dose-related increase in pre-implantation loss with a corresponding decrease in fertility. In rabbits, reduced fetal body weight occurred only in the presence of maternal toxicity (clinical signs, reduced body weight gain and food consumption) at low exposure levels 0.06 times compared to the expected human exposure based on AUCs. The species is known to be sensitive to the effects of antibiotics.</p><p style="text-align:justify">Linezolid and its metabolites are excreted into the milk of lactating rats and the concentrations observed were higher than those in maternal plasma.</p><p style="text-align:justify">Linezolid produced reversible myelosuppression in rats and dogs.</p><p style="text-align:justify">In rats administered linezolid orally for 6 months, non-reversible, minimal to mild axonal degeneration of sciatic nerves was observed at 80 mg/kg/day; minimal degeneration of the sciatic nerve was also observed in 1 male at this dose level at a 3-month interim necropsy. Sensitive morphologic evaluation of perfusion-fixed tissues was conducted to investigate evidence of optic nerve degeneration. Minimal to moderate optic nerve degeneration was evident in 2 of 3 male rats after 6 months of dosing, but the direct relationship to drug was equivocal because of the acute nature of the finding and its asymmetrical distribution. The optic nerve degeneration observed was microscopically comparable to spontaneous unilateral optic nerve degeneration reported in aging rats and may be an exacerbation of common background change.</p><p style="text-align:justify">Preclinical data, based on conventional studies of repeated-dose toxicity and genotoxicity, revealed no special hazard for humans beyond those addressed in other sections of this Summary of Product Characteristics. Carcinogenicity / oncogenicity studies have not been conducted in view of the short duration of dosing and lack of genotoxicity in the standard battery of studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Citric acid anhydrous (E 330)</p><p>Sodium hydroxide (E 524; for pH-adjustment)</p><p>Glucose monohydrate</p><p>Sodium citrate (E 331)</p><p>Hydrochloric acid (E 507; for pH-adjustment)</p><p>Water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Additives should not be introduced into this solution. If linezolid is to be given concomitantly with other drugs, each drug should be given separately in accordance with its own directions for use. Similarly, if the same intravenous line is to be used for sequential infusion of several drugs, the line should be flushed prior to and following linezolid administration with a compatible infusion solution (see section 6.6).</p><p style="text-align:justify">LINID&nbsp;&nbsp; solution&nbsp;&nbsp; for&nbsp;&nbsp; infusion&nbsp;&nbsp; is&nbsp;&nbsp; known&nbsp;&nbsp; to&nbsp;&nbsp; be&nbsp;&nbsp; physically&nbsp;&nbsp; incompatible&nbsp;&nbsp; with&nbsp;&nbsp; the&nbsp;&nbsp;&nbsp; following compounds: amphotericin B, chlorpromazine hydrochloride, diazepam, pentamidine isethionate, erythromycin lactobionate, phenytoin sodium and sulphamethoxazole / trimethoprim. Additionally, it is chemically incompatible with ceftriaxone sodium.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Before opening: 24 months
After opening: From a microbiological point of view, unless the method of opening precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">This medicinal product does not require any special temperature storage conditions; keep the polyethylene container in the outer carton in order to protect from light.</p><p style="text-align:justify">Do not store above&nbsp;30&deg;C</p><p style="text-align:justify">For storage conditions after first opening of the medicinal product, see section 6.3</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LINID is presented as a clear solution in single low-density polyethylene infusion bags containing 300 ml (600mg linezolid) of solution.</p><p>The bags are supplied in boxes of 1 bags. Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">For single use only. Remove only when ready to use, then check for minute leaks by squeezing the bag firmly. If bag leaks, do not use as sterility may be impaired. The solution should be visually inspected prior to use and only clear solutions, without particles should be used. Do not use these bags in series connections. Any unused solution must be discarded. No special requirements for disposal. Any unused medicinal product or waste material should be disposed of in accordance with local requirement. Do not reconnect partially used bags.</p><p style="text-align:justify">LINID is compatible with the following solutions:&nbsp; 5%&nbsp; glucose&nbsp; intravenous&nbsp; infusion,&nbsp; 0.9%&nbsp; sodium&nbsp; chloride&nbsp; intravenous&nbsp; infusion,&nbsp; Ringer-lactate&nbsp; solution&nbsp; for&nbsp; injection&nbsp;&nbsp; (Hartmann&rsquo;s solution for injection).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AJA Pharmaceutical Industries Company, Ltd. 
Hail Industrial City MODON, Street No 32 
PO Box 6979, Hail 55414 
Kingdom of Saudi Arabia
Tel: +966 11 268 7900
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>